Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBT Margin (2019 - 2025)

Historic EBT Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1395.29%.

  • Avidity Biosciences' EBT Margin rose 20364800.0% to 1395.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 2628.53%, marking a year-over-year increase of 1384400.0%. This contributed to the annual value of 2955.44% for FY2024, which is 7417800.0% down from last year.
  • As of Q3 2025, Avidity Biosciences' EBT Margin stood at 1395.29%, which was up 20364800.0% from 4072.37% recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' EBT Margin ranged from a high of 881.69% in Q1 2021 and a low of 7332.36% during Q1 2025
  • Over the past 5 years, Avidity Biosciences' median EBT Margin value was 2023.45% (recorded in 2023), while the average stood at 2470.78%.
  • Data for Avidity Biosciences' EBT Margin shows a peak YoY increase of 20364800bps (in 2025) and a maximum YoY decrease of -53918000bps (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Avidity Biosciences' EBT Margin stood at 2078.4% in 2021, then increased by 12bps to 1822.07% in 2022, then crashed by -51bps to 2751.39% in 2023, then decreased by -25bps to 3446.28% in 2024, then surged by 60bps to 1395.29% in 2025.
  • Its EBT Margin was 1395.29% in Q3 2025, compared to 4072.37% in Q2 2025 and 7332.36% in Q1 2025.